We will study the differences in cellular protein expression between normal and pathological thyroid tissues using proteomics technology, and identified several proteins that are differentially expressed in thyroid lesions with both benign and malignant proliferative potential. The continuation of this line of work will hopefully lead to the discovery of new molecular markers important in the diagnosis and treatment of Thyroid Ca.

Agency
National Institute of Health (NIH)
Institute
Division of Clinical Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC009392-09
Application #
6756954
Study Section
(LP)
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Rodriguez-Canales, J; Hanson, J C; Tangrea, M A et al. (2007) Identification of a unique epigenetic sub-microenvironment in prostate cancer. J Pathol 211:410-9
Wei, M-H; Toure, O; Glenn, G M et al. (2006) Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 43:18-27
Torres-Cabala, Carlos; Bibbo, Marluce; Panizo-Santos, Angel et al. (2006) Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol 50:518-28
Schmidt, Laura S; Nickerson, Michael L; Warren, Michelle B et al. (2005) Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 76:1023-33
Pak, Ho; Gourgiotis, Loukas; Chang, Wen-I et al. (2003) Role of metastasectomy in the management of thyroid carcinoma: the NIH experience. J Surg Oncol 82:10-8